Value
9.5/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 9.8 |
| P/S | 10.0 |
| EV/EBITDA | 7.6 |
| Fwd P/E | 9.8 |
- ▸Forward P/E: 6.3x
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Mativ combines a rare 4-quarter perfect earnings beat streak and a cheap 6.4x forward multiple with real technical and balance-sheet risk, a failed momentum gate, an active death cross, and a leverage penalty from 2.3x debt-to-equity, leaving the position sized at zero conviction despite the catalyst-driven upside case.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
The current price sits 122.6% below the analyst price target, with the sentiment scoring separately citing 162% analyst upside, an unusually wide gap for the sector. Estimated upside | The gap to the analyst target should narrow toward 50-70% as either the price recovers from its current drawdown or analysts trim targets over the next 12 months. | Tripped→Stable |
| CounterA gap this wide more likely reflects stale or overly bullish analyst targets on a small-cap specialty chemicals name than genuine near-term upside potential. | ||
Mativ has beaten earnings estimates in all 4 of its last 4 quarters by an average surprise of 89.37%, and the engine flags earnings in 17 days as a specific catalyst given that streak. Earnings | The beat streak should extend to at least 5 of the next 6 quarters, sustaining the average surprise well above 0%, over the next 12 months. | →Stable |
| CounterA 4-quarter beat streak with an average surprise this large often reflects deliberately conservative guidance that could reverse into a miss once expectations catch up. | ||
The stock trades at a 6.4x forward P/E, which the engine scores as attractively valued relative to its earnings power. Valuation breakdown | The forward P/E multiple should expand from 6.4x toward peer-average levels as the earnings beat streak continues over the next 12 months. | →Stable |
| CounterA persistently low multiple alongside declining revenue and a failed momentum gate can signal the market is correctly discounting structural risk rather than mispricing the stock. | ||
The stock is under a death-cross hard block and failed the momentum gate at a score of 3.6 versus the 4.5 threshold, even though the setup rationale notes MACD is improving. Engine gate (failed) | Momentum score should climb back above 4.5 and the stock should clear the death cross as the recovery setup develops over the next 12 months. | →Stable |
| CounterA confirmed downtrend with the 200-day moving average sloping down at -5.4% per 30 days can persist for extended periods even when short-term momentum indicators like MACD tick up temporarily. | ||
A debt-to-equity ratio of 2.3 triggers a leverage penalty of -1.5 to the overall score, flagged explicitly as a bear-case factor. Bear case | The debt-to-equity ratio should decline from 2.3 toward a lower level as the company delevers over the next 12 months, removing the score penalty. | ↓Deteriorating |
| CounterElevated leverage in a capital-intensive specialty chemicals business is not unusual and can be serviced comfortably given the company's 196% FCF-to-net-income cash conversion. | ||
CounterA gap this wide more likely reflects stale or overly bullish analyst targets on a small-cap specialty chemicals name than genuine near-term upside potential.
CounterA 4-quarter beat streak with an average surprise this large often reflects deliberately conservative guidance that could reverse into a miss once expectations catch up.
CounterA persistently low multiple alongside declining revenue and a failed momentum gate can signal the market is correctly discounting structural risk rather than mispricing the stock.
CounterA confirmed downtrend with the 200-day moving average sloping down at -5.4% per 30 days can persist for extended periods even when short-term momentum indicators like MACD tick up temporarily.
CounterElevated leverage in a capital-intensive specialty chemicals business is not unusual and can be serviced comfortably given the company's 196% FCF-to-net-income cash conversion.
| Component | Sub-score |
|---|---|
| P/E | 9.8 |
| P/S | 10.0 |
| EV/EBITDA | 7.6 |
| Fwd P/E | 9.8 |
| Component | Sub-score |
|---|---|
| ROE | 5.7 |
| ROA | 1.4 |
| Gross margin | 0.0 |
| Op margin | 0.7 |
| Net margin | 1.9 |
| Current ratio | 7.8 |
| FCF quality | 10.0 |
| Moat | 3.6 |
| Piotroski F | 5.6 |
| Component | Sub-score |
|---|---|
| Rev growth | 2.2 |
| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 7.6 |
| OBV | 5.0 |
| MA position | 4.0 |
| Volume | 3.0 |
| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
| Component | Sub-score |
|---|---|
| value rank | 9.6 |
| quality rank | 5.6 |
| growth rank | 1.7 |
| Component | Sub-score |
|---|---|
| bollinger | 4.4 |
| support resistance | 4.1 |
| 52w position | 0.4 |
| gap | 6.0 |
| Component | Sub-score |
|---|---|
| short interest | 8.7 |
| days to cover | 8.4 |
| volatility | 0.5 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 7.7 |
| debt equity | 2.7 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 6.8 |
Multiple concerning factors. Consider reducing position.
L4:PATH_F_SELLSetupRecovery — Death cross but MACD improving, RSI 63
EdgeCatalyst-Driven — Earnings in 12d with 4/4 beat streak
SuitabilitySpeculative — Drawdown -48% (>40% off 52w high)
The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 9.5) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 12.82 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 9.5, Catalyst at 7.4, and Insider at 7.3; the weakest are Growth at 2.2, Technical at 3.7, and Quality at 4.1. The V9 engine flagged 1 failed gate with 3 warnings, producing an asymmetric reward-to-risk of 12.82 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifThe company misses estimates in at least 2 of the next 4 quarters, reversing the current 4-of-4 beat rate.
Trip ifForward P/E stays below 7x for 4 consecutive quarters with no multiple expansion from the current 6.4x reading.
Trip ifThe stock closes below the 200-day moving average for more than 90 consecutive days, confirming the death cross rather than a recovery.
Trip ifDebt-to-equity rises above 3.0x from the current 2.3x, deepening rather than easing the leverage penalty.
Trip ifThe analyst target gap compresses below 50% from the current 122.6%, without the stock price appreciating meaningfully.